Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Journalist with Ebola Arrives at Nebraska Hospital

October 6, 2014 9:57 am | by Josh Funk | News | Comments

An American video journalist who contracted Ebola while working in Liberia has arrived at a Nebraska hospital, where he will be treated for the deadly disease. Ashoka Mukpo, 33, arrived by ambulance Monday at the Nebraska Medical Center, where he will be kept in a specialized biocontainment unit built specifically to handle this type of illness. Read more...

TOPICS:

Sanofi Signs 15-Year Supply Agreement for Wearable Injectors with Unilife

October 6, 2014 9:47 am | News | Comments

Unilife Corporation, a developer and supplier of injectable drug delivery systems, announced the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Read more...

TOPICS:

CEL-SCI Enrolls 16 New Patients in Phase 3 Cancer Trial

October 3, 2014 3:33 pm | News | Comments

CEL-SCI Corp. announced that during the month of September the company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase 3 trial. Read more...             

TOPICS:
Advertisement

New Technology Isolates Tumor Cells from Blood to Optimize Cancer Therapy

October 3, 2014 3:29 pm | News | Comments

A team of bioengineers, molecular biologists, and clinicians used a novel rare cell-sorter to isolate breast cancer cells from the blood of patients, with the aim of identifying the most effective drugs to treat each individual tumor. Read more...

TOPICS:

Fasting Blood Biomarker a-HB Predicts Diabetes Risk

October 3, 2014 3:11 pm | News | Comments

Could a single serum biomarker predict risk for diabetes as accurately as a more complex, hours-long diagnostic procedure? According to researchers at Health Diagnostic Laboratory Inc. and the University of Utah, the answer is "yes." Read more...

TOPICS:

Neurocrine Initiates Clinical Trial for Tourette Syndrome Therapy

October 3, 2014 2:58 pm | News | Comments

Neurocrine Biosciences, Inc. announced that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome. Read more...      

TOPICS:

Halozyme Gets Orphan Drug Designation for Pancreatic Cancer Drug

October 3, 2014 2:49 pm | News | Comments

Halozyme Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Read more...                             

TOPICS:

Record Number of Clinical Trials for Multiple Myeloma this Year

October 3, 2014 2:11 pm | News | Comments

The Multiple Myeloma Research Consortium (MMRC) announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. Read more...

TOPICS:
Advertisement

Potential Therapy Spotted for Sudan Strain of Ebola

October 3, 2014 11:04 am | by Stephanie Guzowski, Editor | Articles | Comments

As the deadly Ebola outbreak in West Africa continues to grip headlines around the world, researchers move steadily forward with drug development. But as essential as it is to contain the current Ebola outbreak, researchers are looking at the bigger picture— and highlighting the need for therapy development to extend beyond the wake of the current epidemic. Read more...

TOPICS:

Ancient Protein-Making Enzyme Moonlights as DNA Protector

October 3, 2014 10:54 am | News | Comments

Scientists at TSRI have found that an enzyme best known for its fundamental role in building proteins has a second major function: to protect DNA during times of cellular stress. Read more...

TOPICS:

Osteoporosis Treatment May also Benefit Breast Cancer Patients

October 3, 2014 10:39 am | News | Comments

Treatment approaches to reduce the risk of metastasis associated with breast cancer may be one step closer to becoming a reality. According to a study led by a team at the Research Institute of the MUCH, findings show that medication used to treat bone deterioration in post-menopausal women may also slow skeletal metastasis caused from breast cancer. Read more...

TOPICS:

Liberia to Prosecute Man Who Brought Ebola to US

October 3, 2014 10:21 am | News | Comments

The Liberian man infected with Ebola who brought the disease to the United States will be prosecuted when he returns home for lying on his airport screening questionnaire, Liberian authorities said. Read more...

TOPICS:

Salix Pharma Scuttles Cosmo Technologies Merger

October 3, 2014 10:10 am | News | Comments

Salix Pharmaceuticals is scrapping its merger with the subsidiary of an Italian drugmaker after the U.S. created new limitations on the tax benefits of incorporating overseas. Read more...

TOPICS:

EU OKs Eli Lilly's $5.4B Bid for Novartis Division

October 3, 2014 10:00 am | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors. Read more...

TOPICS:

Intarcia Announces Positive Results for Type 2 Diabetes Therapy

October 2, 2014 3:33 pm | News | Comments

Intarcia Therapeutics announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 . The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical trial that tested the efficacy and safety of ITCA 650 in patients with type 2 diabetes against placebo. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading